INS and obesity disorder: In agreement with the results from recent clinical studies [31, 33, 46], we found that carvedilol treatment during HFD-induced obesity improved glucose tolerance and insulin sensitivity possibly by suppressing the hepatic glucose overproduction and enhancing the muscular insulin signaling pathway.